{"id":"reteplase-10-u","safety":{"commonSideEffects":[{"rate":null,"effect":"Bleeding (including intracranial hemorrhage)"},{"rate":null,"effect":"Reperfusion arrhythmias"},{"rate":null,"effect":"Hypotension"},{"rate":null,"effect":"Allergic reactions"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Reteplase is a recombinant tissue plasminogen activator (tPA) that works by binding to fibrin in blood clots and catalyzing the conversion of plasminogen to plasmin. Plasmin then degrades the fibrin matrix that holds the clot together, leading to clot dissolution. This restores blood flow in occluded vessels, particularly in acute myocardial infarction.","oneSentence":"Reteplase is a fibrinolytic enzyme that breaks down blood clots by converting plasminogen to plasmin, which degrades fibrin.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:04:57.135Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute myocardial infarction (AMI) for thrombolysis"}]},"trialDetails":[{"nctId":"NCT00178620","phase":"PHASE4","title":"Pre-hospital Administration of Thrombolytic Therapy With Urgent Culprit Artery Revascularization","status":"COMPLETED","sponsor":"The University of Texas Health Science Center, Houston","startDate":"2003-09","conditions":"Heart Disease, Myocardial Infarction, Acute Myocardial Infarction","enrollment":390},{"nctId":"NCT00806403","phase":"PHASE4","title":"Comparison Between Thrombolysis and Primary Percutaneous Coronary Intervention (PCI) to Treat ST-Segment Elevation Myocardial Infarction","status":"COMPLETED","sponsor":"Sahlgrenska University Hospital","startDate":"2001-11","conditions":"Acute Myocardial Infarction","enrollment":205}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Retavase"],"phase":"marketed","status":"active","brandName":"Reteplase 10 U","genericName":"Reteplase 10 U","companyName":"The University of Texas Health Science Center, Houston","companyId":"the-university-of-texas-health-science-center-houston","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Reteplase is a fibrinolytic enzyme that breaks down blood clots by converting plasminogen to plasmin, which degrades fibrin. Used for Acute myocardial infarction (AMI) for thrombolysis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}